Cohance Lifesciences Share price

COHANCE

Healthcare Large Cap

456.3

28.35 (-5.85%)

NSE

BSE

Last updated on 13 May, 2026 | 15:56 IST

BUYSELL

Today's High

474.80

Today's Low

443.00

52 Week Low

266.70

52 Week High

1123.40

Free Demat with Zero AMC*

Cohance Lifesciences Chart

ChartIQ

TradingView

Cohance Lifesciences Share Key Metrics

Volume

50.89 L

Market Cap

17456.54 CR

LTQ@LTP

40@456.30

ATP

458.95 Var Margin

100 %

Circuit Range

387.75-581.55

Delivery %

13.36 %

Value

233.58 CR

ASM/GSM

No

Market Lot

1

Summary

13 May, 2026 | 15:56 को, Cohance Lifesciences का शेयर प्राइस आज ₹456.3 पर है, जो दिन के लिए 28.35% की -5.85 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹443.00 और ₹474.80 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹266.70 से ₹1123.40 तक रही है। ट्रेडिंग गतिविधि के मामले में, Cohance Lifesciences ने 5089451 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹382567140 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹45895 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 40,45630 रही। यह स्टॉक ₹387.75-581.55 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹233.58 CR है। दिन के लिए डिलीवरी परसेंटेज 13.36% रही। इसके अतिरिक्त, Cohance Lifesciences वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Cohance Lifesciences Fundamentals

P/E Ratio

90.79

P/B Ratio

4.8

Div. Yield

0

Sector P/E

68.8

Sector P/B

3.58

Sec. Div. Yield

0.56

Cohance Lifesciences Resistance and Support

Pivot 484.38

Resistance

First Resistance

505.26

Second Resistance

525.88

Third Resistance

546.76

Support

First Support

463.76

Second Support

442.88

Third Support

422.26

Cohance Lifesciences Shareholding Pattern

2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

57.49%

Mutual Fund

18.57%

Insurance

3.13%

Foreign Institutional Investors

5.59%

Domestic Institutional Investors

0.1%

Retail

15.12%

Others

0%

Total Promoters

MAR '26

57.49%

Cohance Lifesciences Corporate Actions

Date	Agenda
2026-05-12	Audited Results
2026-02-12	Quarterly Results

Cohance Lifesciences News

Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4

Cohance Lifesciences shares slipped by 7% after Jefferies downgraded the stock from 'Buy' to 'Hold' and reduced its target price, citing a weak fourth-quarter outlook.

May 13 2026 10:05:00

Q4 Results Highlights: Texmaco Rail profit at ₹57.7 crore; Cohance Lifesciences profit at ₹20 crore

Cohance Lifesciences is scheduled to announce its financial results for the fourth quarter of fiscal year 2026 on May 12, 2026, alongside several other companies as the earnings season progresses. [1, 2, 4]

May 12 2026 22:05:00

Cohance Lifesciences Ltd - 543064 - Board Meeting Outcome for Outcome Of The Board Meeting

Cohance Lifesciences reported FY26 consolidated revenue of ₹22.69 bn (down 13% YoY) and net profit of ₹1.84 bn (down 65.4% YoY). The Q4 consolidated revenue declined 26.3% YoY to ₹6.19 bn, with net profit falling 76.5% YoY to ₹0.33 bn, influenced by inventory adjustments and pricing pressures. The Board also revised its KMP materiality policy.

May 12 2026 17:05:00

Cohance Lifesciences Limited

Cohance Lifesciences board will meet on May 12, 2026, to consider and approve the yearly audited standalone and consolidated financial results for the period ended March 2026. This meeting will finalize the company's financial performance for the full fiscal year.

May 06 2026 15:05:00

Cohance Lifesciences Ltd - 543064 - Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company, For The Quarter And Financial Year Ended March 31, 2026.

Cohance Lifesciences board is scheduled to meet on May 12, 2026, to consider and approve its audited financial results for the quarter and full financial year ended March 31, 2026. This meeting will review both standalone and consolidated financials.

May 06 2026 15:05:00

Cohance Lifesciences shares need to cross this level to recover all the losses for 2026

Cohance Lifesciences shares are noted to require crossing the ₹118.5 level to recover 2026 losses, following a recent price fluctuation from ₹100 to ₹130 and subsequent retracement. Technical analysis suggests ₹118.5 is a key resistance for a rebound, with a support level identified at ₹99.

Apr 28 2026 11:04:00

Cohance Lifesciences Limited

Vivek Sharma has resigned as Cohance Lifesciences' Executive Chairman and Director, effective April 30, 2026. The departure is due to personal reasons, as stated in his letter.

Apr 27 2026 20:04:00

Cohance Lifesciences Limited

Cohance Lifesciences announced key management changes with Mr. Umang Vohra appointed as Chairman effective May 1, 2026. This follows the resignation of Mr. Vivek Sharma as Executive Chairman, effective April 30, 2026, due to personal reasons. Mr. Vohra has over 30 years of experience, including roles as MD and Global CEO at Cipla.

Apr 27 2026 20:04:00

Gainers & Losers: Cohance Lifesciences and IndusInd Bank among 9 big movers on Monday

Cohance Lifesciences was identified as one of the top stock market gainers on Monday, following the announcement of Umang Vohra's appointment as the new Chairman and Chief Executive Officer.

Apr 27 2026 17:04:00

Cohance Lifesciences Limited

Cohance Lifesciences appointed Umang Vohra as Chairman and Group CEO. He brings over 30 years of leadership experience from companies like PepsiCo India, Dr. Reddy's Laboratories, and Cipla Limited, where he previously served as MD and Global CEO.

Apr 27 2026 14:04:00

NSE : 17945

BSE : 543064

ISIN : INE03QK01018

Cohance Lifesciences Management

Name	Position
Vivek Sharma	Chairman
Umang Vohra	Additional Director

Cohance Lifesciences Similar Stocks

Natco Pharma Ltd.

1171.90

-10.00 (0.85%)

Onesource Specialty Pharma Ltd.

1789.80

-40.40 (2.21%)

Eris Lifesciences Ltd.

1330.60

-27.00 (1.99%)

Astrazeneca Pharma India Ltd.

8376.00

56.00 (0.67%)

Granules India Ltd.

728.35

-0.70 (0.10%)

Poly Medicure Ltd.

1597.70

-73.40 (4.39%)

Jubilant Pharmova Ltd.

995.40

7.30 (0.74%)

Alembic Pharmaceuticals Ltd.

767.85

-0.30 (0.04%)

Dr. Agarwal's Health Care Ltd.

448.00

-2.20 (0.49%)

Caplin Point Laboratories Ltd.

1841.80

26.80 (1.48%)

Cohance Lifesciences FAQs

Cohance Lifesciences शेयर का खरीद मूल्य 456.3 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Cohance Lifesciences शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Cohance Lifesciences शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 90.79 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Cohance Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.8 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Cohance Lifesciences शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.58 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Cohance Lifesciences का मार्केट कैप 17456.54 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Cohance Lifesciences शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 1123.40 और 266.70 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Open Account Now